Marker Therapeutics (MRKR) Expected to Announce Quarterly Earnings on Wednesday

Posted by Casey Walker on May 20th, 2025

Marker Therapeutics (NASDAQ:MRKR – Get Free Report) is expected to be releasing its Q1 2025 earnings data before the market opens on Wednesday, May 21st. Analysts expect Marker Therapeutics to post earnings of ($0.66) per share and revenue of $0.50 million for the quarter.

Marker Therapeutics (NASDAQ:MRKR – Get Free Report) last issued its quarterly earnings data on Monday, March 31st. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.14). Marker Therapeutics had a negative net margin of 179.74% and a negative return on equity of 89.63%. The business had revenue of $1.22 million during the quarter, compared to the consensus estimate of $5.25 million. On average, analysts expect Marker Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Marker Therapeutics Price Performance

Marker Therapeutics stock remained flat at $1.13 during mid-day trading on Tuesday. 32,768 shares of the company’s stock traded hands, compared to its average volume of 62,589. Marker Therapeutics has a 52-week low of $0.95 and a 52-week high of $5.99. The firm’s 50 day moving average price is $1.17 and its two-hundred day moving average price is $2.19. The firm has a market capitalization of $12.79 million, a PE ratio of -0.85 and a beta of 1.29.

Analysts Set New Price Targets

A number of research firms have commented on MRKR. Canaccord Genuity Group started coverage on shares of Marker Therapeutics in a report on Wednesday, March 5th. They issued a “buy” rating and a $8.00 price target for the company. WBB Securities reaffirmed a “strong-buy” rating and set a $12.50 target price on shares of Marker Therapeutics in a research report on Tuesday, April 1st. Finally, Brookline Capital Management raised Marker Therapeutics to a “strong-buy” rating in a research report on Monday, February 10th.

Check Out Our Latest Research Report on MRKR

About Marker Therapeutics

(Get Free Report)

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.